首页> 美国卫生研究院文献>Psychiatry Investigation >Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourettes Disorder with Clonidine Extended Release
【2h】

Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourettes Disorder with Clonidine Extended Release

机译:可乐定缓释片治疗注意力不足过动症和/或图雷特氏病的儿童和青少年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We aimed to assess the effectiveness and safety of clonidine extended release (ER) treatment in Korean youth with ADHD and/or Tourette's disorder. We retrospectively reviewed the medical records of 29 children and adolescents treated with clonidine ER. The effectiveness were retrospectively measured at baseline and after 4 and 12 weeks based on the Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety was evaluated at each visit based on spontaneous reports from the subjects or from their parents/guardians. Significant decreases in the CGI-S scores for both ADHD (F=23.478, p<0.001, partial η2=0.540) and tic symptoms (F=15.137, p<0.001, partial η2=0.443) were noted over 12 weeks. The most common adverse event was somnolence (n=9, 31.0%) and life-threatening adverse effects were not observed. Our results provide preliminary evidence for the effectiveness and safety of clonidine ER.
机译:我们旨在评估可乐定缓释(ER)治疗在患有ADHD和/或Tourette病的韩国青年中的有效性和安全性。我们回顾性检查了使用可乐定ER治疗的29名儿童和青少年的病历。根据临床总体印象严重度(CGI-S)和临床总体印象改善(CGI-I)评分,在基线,4周和12周后对疗效进行回顾性测量。每次访视时均根据受试者或其父母/监护人的自发报告评估安全性。在12周内,ADHD(F = 23.478,p <0.001,部分η2= 0.540)和抽动症状(F = 15.137,p <0.001,部分η2= 0.443)的CGI-S评分均显着下降。最常见的不良事件是嗜睡(n = 9,31.0%),未观察到威胁生命的不良反应。我们的结果为可乐定ER的有效性和安全性提供了初步证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号